TY - JOUR
T1 - Characterization of a novel recombinant calcium-binding protein from Arca subcrenata and its anti-hepatoma activities in vitro and in vivo
AU - Shi, Hui
AU - Panjikar, Santosh
AU - Li, Chunlei
AU - Ou, Xiaozheng
AU - Zhou, Yun
AU - Zhang, Kunhao
AU - Song, Liyan
AU - Yu, Rongmin
AU - Sun, Lianli
AU - Zhu, Jianhua
N1 - Funding Information:
This research work was financially supported by the National Natural Science Foundation of China (No. 82003910 and 82204583 ), the Special Fund for Talent Development of Jinan (No. 2021GXRC072 ) and the Guangdong Basic and Applied Basic Research Foundation (No. 2023A1515012077 ). The authors thank the staff of BL17B1, BL17U1, and BL19U1 beamlines at the National Center for Protein Science Shanghai and Shanghai Synchrotron Radiation Facility (Shanghai, China) for the help with data collection.
Publisher Copyright:
© 2023 Elsevier B.V.
PY - 2023/8/1
Y1 - 2023/8/1
N2 - Previous studies demonstrated that ASP-3 was a novel calcium-binding protein from Arca subcrenata that effectively inhibited the proliferation of HepG2 cells. To further study the antitumor activity and mechanism of ASP-3, the cytotoxic effects of recombinant ASP-3 were evaluated in HepG2 cells. The results demonstrated that ASP-3 inhibited the proliferation of HepG2 cells by competitively binding to the EGF binding pocket of EGFR and inhibiting the JAK-STAT, RAS-RAF-MEK-ERK, and PI3K-Akt-mTOR signaling pathways mediated by EGFR. ASP-3 significantly inhibited tumor growth in a HepG2 cell subcutaneous xenograft nude mouse model, and its (25 mg/kg and 75 mg/kg) tumor inhibition rates were 46.92 % and 60.28 %, respectively. Furthermore, the crystal structure of ASP-3 was resolved at 1.4 Å. ASP-3 formed as a stable dimer and folded as an EF-Hand structure. ASP-3 stably bound to domain I and domain III of the EGFR extracellular region by using molecular docking and molecular dynamics simulation analysis. Compared with the endogenous ligand EGF, ASP-3 displayed a stronger interaction with EGFR. These experimental results indicated that recombinant ASP-3 possessed an effective anti-hepatoma effect. So, it might be a potential molecule for liver cancer therapy.
AB - Previous studies demonstrated that ASP-3 was a novel calcium-binding protein from Arca subcrenata that effectively inhibited the proliferation of HepG2 cells. To further study the antitumor activity and mechanism of ASP-3, the cytotoxic effects of recombinant ASP-3 were evaluated in HepG2 cells. The results demonstrated that ASP-3 inhibited the proliferation of HepG2 cells by competitively binding to the EGF binding pocket of EGFR and inhibiting the JAK-STAT, RAS-RAF-MEK-ERK, and PI3K-Akt-mTOR signaling pathways mediated by EGFR. ASP-3 significantly inhibited tumor growth in a HepG2 cell subcutaneous xenograft nude mouse model, and its (25 mg/kg and 75 mg/kg) tumor inhibition rates were 46.92 % and 60.28 %, respectively. Furthermore, the crystal structure of ASP-3 was resolved at 1.4 Å. ASP-3 formed as a stable dimer and folded as an EF-Hand structure. ASP-3 stably bound to domain I and domain III of the EGFR extracellular region by using molecular docking and molecular dynamics simulation analysis. Compared with the endogenous ligand EGF, ASP-3 displayed a stronger interaction with EGFR. These experimental results indicated that recombinant ASP-3 possessed an effective anti-hepatoma effect. So, it might be a potential molecule for liver cancer therapy.
KW - Anti-hepatoma activity
KW - Arca subcrenata protein
KW - Crystal structure
KW - Molecular dynamics simulations
UR - https://www.scopus.com/pages/publications/85163362422
U2 - 10.1016/j.ijbiomac.2023.125513
DO - 10.1016/j.ijbiomac.2023.125513
M3 - Article
C2 - 37353116
AN - SCOPUS:85163362422
SN - 0141-8130
VL - 245
JO - International Journal of Biological Macromolecules
JF - International Journal of Biological Macromolecules
M1 - 125513
ER -